$NTLA News

Intellia (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary

Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative?

Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics (NASDAQ:NTLA) Slips on Q2 Revenue Miss Despite In-Line Loss

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

Intellia: Phase 3 HAELO Win Doesn't Fix The Commercial Problem

Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Intellia Therapeutics: An Overvalued Biotech With Little To No Commercial Potential

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)